# SSX7

## Overview
The SSX7 gene encodes the protein SSX family member 7, which is part of the synovial sarcoma X (SSX) gene family. This family is characterized by its role in encoding proteins that are often expressed in cancer-testis antigens, making them relevant in oncological research. SSX family member 7 is implicated in various cancers, including prostate cancer and synovial sarcoma, due to its aberrant expression patterns. The protein is involved in signal transduction pathways, such as the epidermal growth factor receptor pathway, which are critical in cancer development and progression. The study of SSX7 has highlighted its potential as a biomarker for cancer diagnostics and therapeutics, particularly in understanding ethnic variations in cancer susceptibility and response (Adeola2016Novel; Pan2021CRTC1–SS18).

## Clinical Significance
SSX7, a member of the SSX gene family, is associated with cancer-testis antigens and has been implicated in various cancers. Alterations in SSX7 expression have been linked to prostate cancer (PCa), where it is part of a network of genes that may play a role in PCa pathogenesis. The study of a South African cohort identified SSX7 among differentially expressed antigens between PCa and benign conditions, suggesting its potential involvement in signal transduction pathways relevant to cancer development (Adeola2016Novel).

In synovial sarcoma, the SSX family, including SSX7, is noted for its ectopic expression in various cancers. Although specific diseases or conditions directly resulting from SSX7 mutations are not detailed, the SSX family is generally associated with oncogenesis due to their aberrant expression in tumors (Pan2021CRTC1–SS18).

The potential of SSX7 as a biomarker for PCa and its involvement in common signaling pathways such as the epidermal growth factor receptor pathway highlight its clinical significance. These findings suggest that SSX7 could be a target for cancer diagnostics and therapeutics, particularly in understanding racial variations in autoantibody responses among different ethnic groups (Adeola2016Novel).


## References


[1. (Adeola2016Novel) Henry A. Adeola, Muneerah Smith, Lisa Kaestner, Jonathan M. Blackburn, and Luiz F. Zerbini. Novel potential serological prostate cancer biomarkers using ct100+ cancer antigen microarray platform in a multi-cultural south african cohort. Oncotarget, 7(12):13945–13964, February 2016. URL: http://dx.doi.org/10.18632/oncotarget.7359, doi:10.18632/oncotarget.7359. This article has 33 citations and is from a poor quality or predatory journal.](https://doi.org/10.18632/oncotarget.7359)

[2. (Pan2021CRTC1–SS18) Rui Pan, Ziyu Wang, Xiaotong Wang, Ru Fang, Qiuyuan Xia, and Qiu Rao. Crtc1–ss18 fusion sarcoma with aberrant anaplastic lymphoma kinase expression. International Journal of Surgical Pathology, 30(1):99–105, May 2021. URL: http://dx.doi.org/10.1177/10668969211021997, doi:10.1177/10668969211021997. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/10668969211021997)